Physician profile
Asma Syed
NPI 1306937784
$49,080.03
in general payments reported to CMS, 2019-2025
45 companies · $4,044 in 2025
The $4,044 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,111 · 2020: $8,436 · 2021: $13K · 2022: $2,441 · 2023: $8,957 · 2024: $7,663 · 2025: $4,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $5,531 · Consulting Fee: $3,053 · Travel and Lodging: $1,510 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,500.00 |
| Food and Beverage | $5,530.88 |
| Consulting Fee | $3,052.61 |
| Travel and Lodging | $1,510.16 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26,163.74 | 2019-2025 | Lifevest |
| Biosense Webster, INC. | $4,555.17 | 2019-2025 | Carto 3 |
| Medtronic, INC. | $4,147.32 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Advisa Dr Mri Surescan |
| Medtronic Vascular, INC. | $3,261.18 | 2019-2020 | |
| Abbott Laboratories | $2,306.77 | 2019-2024 | Accent, Cardiomems |
| Kestra Medical Technology Services, INC. | $2,153.73 | 2024-2025 | Assure Wcd |
| Aop Health US, LLC | $966.78 | 2025 | Rapiblyk |
| Boston Scientific Corporation | $895.26 | 2019-2025 | General - Therapies, General - Tachy, Vigilant X4 Crt-D |
| Novartis Pharmaceuticals Corporation | $577.53 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $417.71 | 2020-2025 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $306.35 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $279.14 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $249.13 | 2020-2025 | |
| Bardy Diagnostics, INC. | $231.56 | 2020 | |
| Merck Sharp & Dohme LLC | $226.82 | 2023-2025 | Verquvo, Winrevair |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.